Acquisitions, Investments and Licenses (Tables)

6 Months Ended

Jun. 30, 2017

Business Acquisition [Line Items]

Accounting Method, Carrying Value and Underlying Equity in Net Assets of Unconsolidated Investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of June 30, 2017:

(in thousands)
Investment type	Investment Carrying Value		Underlying Equity in Net Assets
Equity method investments	$	24,353	$	26,421
Variable interest entity, equity method	212		—
Available for sale investments	3,785
Cost method investment	2,608
Warrants and options	3,537
Total carrying value of investments	$	34,495

Transition Therapeutics

Business Acquisition [Line Items]

Purchase Price Allocation

The following table summarizes the preliminary purchase price allocation and the estimated fair value of the net assets acquired and liabilities assumed at the date of acquisition. The purchase price allocation for Transition Therapeutics is preliminary pending completion of the fair value analysis of acquired assets and liabilities:

(In thousands)	Transition Therapeutics
Cash and cash equivalents	$	15,878
IPR&D assets	41,000
Goodwill	3,453
Other assets	634
Accounts payable and other liabilities	(1,035		)
Deferred tax liability	(1,400		)
Total purchase price	$	58,530